← Back to headlines
BridgeBio Downgraded by Raymond James Following Pfizer Drug's Loss of Exclusivity
BridgeBio has received a downgrade from Raymond James, attributed to the loss of exclusivity for Pfizer's drug Vyndamax.
26 May, 13:25 — 26 May, 13:25
Sources
Showing 1 of 1 sources
